Johnson & Johnson MedTech Partners with Qure.ai to Advance AI-Powered Lung Cancer Detection in India
• Johnson & Johnson MedTech and Qure.ai have launched Project BreatheEZ to establish AI-led Incidental Pulmonary Nodule Detection clinics across India, with the first clinic opening in Tamil Nadu.
• The initiative will deploy AI technology across 10 hub medical centers and 20 supporting spoke sites to enhance early detection of lung cancer, particularly in underserved tier-2 and tier-3 cities.
• With cancer burden in India projected to rise from 26.7 million DALYs in 2021 to 29.8 million by 2025, this partnership aims to transform lung cancer care through AI-powered screening of X-rays and CT scans.
Lupus Nephritis Market Expected to Grow as Novel Therapies Enter Clinical Trials
• The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions.
• Several innovative therapies are advancing through clinical trials, including CAR-T cell treatments from companies like Allogene Therapeutics, Adicet Bio, and Caribou Biosciences, which received FDA Fast Track designations.
• Key pharmaceutical players including Aurinia Pharmaceuticals, AstraZeneca, and Roche are developing treatments such as voclosporin, anifrolumab, and obinutuzumab to address the significant unmet needs in lupus nephritis management.
Adrenoleukodystrophy: Emerging Therapies Show Promise in Clinical Trials
• Multiple companies are developing novel therapies for Adrenoleukodystrophy (ALD), a rare genetic disorder affecting the adrenal glands and nervous system.
• Key emerging therapies include ABX-002 (Autobahn Therapeutics), VK0214 (Viking Therapeutics), and SBT101 (SwanBio Therapeutics), among others, targeting various aspects of the disease.
• Leriglitazone (MIN102) by Minoryx Therapeutics faced a setback with a negative CHMP opinion, but a re-examination for conditional approval is planned.
• Clinical trials are exploring different routes of administration, including intravenous, subcutaneous, and oral, with diverse molecule types such as monoclonal antibodies and small molecules.
U.S. Tuberous Sclerosis Drug Market Projected to Reach $1.25 Billion by 2030, Growing at 23.1% CAGR
• The U.S. tuberous sclerosis drug market is expected to grow from $237.2 million in 2022 to $1.25 billion by 2030, driven by FDA approvals of new treatments and increasing disease prevalence.
• FDA-approved treatments include Afinitor (everolimus) for patients aged 2 and above, approved in 2018, and Epidiolex (cannabidiol) for patients aged 1 and above, approved in 2020.
• mTOR inhibitors are gaining significant traction in treatment protocols, showing effectiveness for internal tumors and skin lesions, with FDA approval for treating lung complications like Lymphangioleiomyomatosis (LAM) in 2015.
© Copyright 2025. All Rights Reserved by MedPath